SBIR PHASE II: Marker Gene Directed Substrates for Cell Regulation

*9710722纳尔韦这个小企业创新研究第二阶段项目旨在开发能够利用转化细胞中的共同标记基因表达来控制活组织中细胞的生长和特征的结合物的新商业用途。从我们在第一阶段的成功中，我们建议进行研究，以提供推动这些重组基因系统在生物技术中的商业应用所需的突破。在该项目的第二阶段，Marker基因技术公司建议通过制备常见生长调节剂、药物和酶抑制剂的新结合物来建立这项技术，用于组织培养中含有基因融合标记基因的各种动物细胞或细菌。此外，标记基因技术公司将开发新的载体和系统，用于在体内对标记基因进行明确的控制。这些新的结合系统将提供检测基因融合的创新方法，并利用这些融合系统在体内转化的细胞中控制这些细胞的特定生物学特性。研究的潜在商业应用这一项目的成功为遗传疾病的医疗干预、新的药物输送系统以及在细胞培养系统中改进新蛋白质和药物的生物技术生产领域开辟了商业可能性。***

*** 9710722 Naleway This Small Business Innovation Research Phase II project aims to develop new commercial uses of conjugates capable of exploiting common marker gene expression in transformed cells to control the growth and character of cells in living tissue. From our successes in Phase I we propose research that will provide breakthroughs needed to advance commercial uses of these recombinant gene systems in biotechnology. In Phase II of this project, Marker Gene Technologies, Inc. proposes to establish this technology by preparing new conjugates of common growth regulators, drugs and enzyme inhibitors, for administration to a variety of animal cells or bacteria in tissue culture that contain gene fusion marker genes. In addition, Marker Gene Technologies, Inc. will develop new vectors and systems for defined control of marker genes in vivo. These new conjugate systems will provide innovative methods of detecting gene fusions and utilizing these fusion systems in transformed cells in vivo to control selected biological properties of these cells. Potential Commercial Applications of the Research The success of this project opens up commercial possibilities in the fields of medical intervention in genetic diseases, new drug delivery systems, and improved biotechnological production of new proteins and drugs in cell-culture systems. ***